Lancet Rheumatology最新文献

{"title":"Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial","authors":"Katya Meridor, Raquel Granados, Stephanie R Harrison, Philip S Helliwell, Dennis McGonagle, Gabriele De Marco, Helena Marzo-Ortega","doi":"10.1016/S2665-9913(26)00120-7","DOIUrl":"10.1016/S2665-9913(26)00120-7","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 7","pages":"Pages e504-e506"},"PeriodicalIF":29.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147876106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silent patients, silent disease: misalignment in patient-initiated follow-up","authors":"Yuanyuan Hu, Hao Wang, Hui Li","doi":"10.1016/S2665-9913(26)00149-9","DOIUrl":"10.1016/S2665-9913(26)00149-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 7","pages":"Page e507"},"PeriodicalIF":29.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148206626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10 years of SAGER sees progress, but not parity","authors":"The Lancet Rheumatology","doi":"10.1016/S2665-9913(26)00185-2","DOIUrl":"10.1016/S2665-9913(26)00185-2","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 7","pages":"Page e493"},"PeriodicalIF":29.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial","authors":"Wing-Yi Wong MD, Dewi Rijnenberg MD, Valentin M D Baloche PhD, Sofie L M Blokland PhD, Paco M J Welsing PhD, Femke Bonte-Mineur MD, Cornelis P J Bekker PhD, Safae Hamkour MD, Céline Bogers MD, Noortje Groot PhD, Prof Helen L Leavis PhD, Dr Joël A G van Roon PhD","doi":"10.1016/S2665-9913(26)00075-5","DOIUrl":"10.1016/S2665-9913(26)00075-5","url":null,"abstract":"<div><h3>Background</h3><div>Sjögren's disease is a systemic autoimmune disease characterised by secretory gland dysfunction that lacks effective systemic treatment. We aimed to replicate the findings of the RepurpSS-I trial and determine the efficacy and safety of leflunomide and hydroxychloroquine combination therapy as a first conventional treatment for Sjögren's disease.</div></div><div><h3>Methods</h3><div>This randomised, placebo-controlled, double-blind, phase 2b trial (RepurpSS-II) was done at University Medical Center Utrecht, The Netherlands. Eligible patients were adults aged 18–75 years with an European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) of at least 5. Exclusion criteria included an active wish to conceive within 2 years or use of leflunomide or hydroxychloroquine in the past 6 months. Patients were randomly assigned (1:1) to receive placebo or leflunomide (20 mg) and hydroxychloroquine (400 mg) orally, once a day. Investigators, patients, and laboratory staff were masked to treatment until 24 weeks. The primary endpoint was the between-group difference in change in ESSDAI from baseline to 24 weeks. Primary and secondary analyses were done in the intention-to-treat population using mixed-effect analysis, accounting for repeated outcome assessment and controlling for baseline ESSDAI. This study was registered with the European Union Clinical Trials Register (EudraCT 2020-001933-11) and is completed. Patients from the RepurpSS-I trial and Sjögren's disease patient representatives contributed to the study design.</div></div><div><h3>Findings</h3><div>Between Oct 12, 2021, and July 5, 2024, 243 patients were approached for inclusion. 158 were excluded before screening and 39 were excluded following screening. 46 patients were enrolled and randomly assigned to receive leflunomide–hydroxychloroquine (n=21) or placebo (n=25). Median age was 55·00 years (IQR 51·00–60·50). 43 (93%) of 46 patients were female and three (7%) were male. The mean difference in ESSDAI between the leflunomide–hydroxychloroquine group and placebo group at 24 weeks was –4·135 (95% CI –6·558 to –1·709, p=0·0012). One serious adverse event occurred in the treatment group; probably unrelated to study medication (hospital admission for myocardial infarction). Adverse events were similar between groups; gastrointestinal discomfort was most common (six [29%] of 21 patients in the leflunomide–hydroxychloroquine group and four [16%] of 25 in the placebo group). There were no deaths during the study.</div></div><div><h3>Interpretation</h3><div>This study supports previous findings that leflunomide in combination with hydroxychloroquine is an effective treatment for systemically active Sjögren's disease and was generally well tolerated. This therapy might be an affordable and widely available option for patients with active systemic Sjögren's disease. Future studies should investigate whether this combination is effectiv","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 7","pages":"Pages e528-e538"},"PeriodicalIF":29.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary haemophagocytic syndrome induced by levamisole-associated vasculitis.","authors":"Luis Javier Cajas Santana, Jhon Mora, Valentina López, Andrés Siabatto","doi":"10.1016/S2665-9913(26)00078-0","DOIUrl":"https://doi.org/10.1016/S2665-9913(26)00078-0","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits","authors":"Laura C M Schenning MD ,&nbsp;Marieke van Onna MD PhD ,&nbsp;Prof Sander W Tas MD","doi":"10.1016/S2665-9913(25)00321-2","DOIUrl":"10.1016/S2665-9913(25)00321-2","url":null,"abstract":"<div><div>Glucocorticoid pulse therapy is commonly prescribed by rheumatologists worldwide for a wide variety of serious and potentially life-threatening diseases. Pulse therapy also has the potential to lower the cumulative glucocorticoid burden, which has already been proven in systemic lupus erythematosus and giant cell arteritis. The standard practice in rheumatology is to administer this therapy intravenously, but current literature suggests that oral methylprednisolone is a non-inferior option for clinical outcomes and safety. Integrating oral methylprednisolone pulse therapy into rheumatological practice might have considerable benefits, not only for patients but also for society as a whole. In this Viewpoint, we provide a review of oral methylprednisolone pulse therapy covering pharmacology, safety, patient preference, sustainability, and its possible use in rheumatology practice. We aim to increase awareness among rheumatologists of the potential use of oral glucocorticoid pulse therapy as this modest change in clinical practice has major benefits.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 3","pages":"Pages e228-e231"},"PeriodicalIF":16.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145794828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal variation in haemophagocytic lymphohistiocytosis mortality","authors":"Fernando Tornero-Romero ,&nbsp;Lara Cantero-del Olmo ,&nbsp;Miguel Morante-Ruiz ,&nbsp;Lage-Estébanz Fernando","doi":"10.1016/S2665-9913(26)00008-1","DOIUrl":"10.1016/S2665-9913(26)00008-1","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 3","pages":"Pages e166-e167"},"PeriodicalIF":16.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146097203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forging ahead on fibromyalgia","authors":"The Lancet Rheumatology","doi":"10.1016/S2665-9913(26)00051-2","DOIUrl":"10.1016/S2665-9913(26)00051-2","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 3","pages":"Page e159"},"PeriodicalIF":16.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147311300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pneumatosis cystoides intestinalis in overlap syndrome","authors":"May Shuen Tang MRCP ,&nbsp;Gim Gee Teng MBBS","doi":"10.1016/S2665-9913(25)00075-X","DOIUrl":"10.1016/S2665-9913(25)00075-X","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 3","pages":"Page e232"},"PeriodicalIF":16.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early screening for rheumatoid arthritis-associated interstitial lung disease: statistical nuances challenge the role of disease activity – Authors' reply","authors":"Gregory C McDermott ,&nbsp;Misti L Paudel ,&nbsp;Marcy B Bolster ,&nbsp;Kevin D Deane ,&nbsp;Dinesh Khanna ,&nbsp;Bryant R England ,&nbsp;Jeffrey A Sparks","doi":"10.1016/S2665-9913(26)00004-4","DOIUrl":"10.1016/S2665-9913(26)00004-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"8 3","pages":"Pages e165-e166"},"PeriodicalIF":16.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}